Absci announces strategic R&D partnership with PrecisionLife to develop AI-enabled drug pipeline

Absci Corp

Partnership combines Absci's generative AI antibody design with PrecisionLife's disease biology to develop up to five drug targets.
With this partnership, Absci has signed ten new Active Programs in 2023, achieving its full-year outlook.
Collaboration aims to create a shared pipeline of novel biotherapeutics for chronic diseases with unmet medical needs.
Absci and PrecisionLife will jointly evaluate options to advance programs and share in potential value.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.